General Archive
-
News releasesCould an existing antibiotic be used to treat rare liver disease?
A new international clinical trial funded by medical research organisation LifeArc will test whether oral vancomycin, an existing antibiotic, could…
-
VITALITY Trial: Repurposing an existing antibiotic for PSC-IBD
VITALITY Trial: Repurposing an existing antibiotic for PSC-IBD We’re supporting a Phase 2b/3 clinical trial to investigate whether the oral…
-
News releasesNew study brings hope for children with rare life-threatening kidney disease
We’re proud to have funded new research with Great Ormond Street Hospital Charity (GOSH Charity) and Kidney Research UK that…
-
Elpida Therapeutics: Accelerating gene therapies for ultra‑rare neurodegenerative diseases
-
Investigating a novel gene therapy for CTLA-4 insufficiency
-
Evaluation of the effect of intranasal insulin on development and behaviour in Phelan-McDermid syndrome
-
Advancing Repurposed Therapeutics for Epidermolysis Bullosa (ART-EB)
-
News releasesIntroducing Raremap: a new way to navigate the rare disease landscape
LifeArc has collaborated with Rare Disease Research UK to launch Raremap, the UK’s first directory of rare disease organisations. There’s a vibrant…
-
News releasesNew boost for personalised rare disease treatments as the Rare Therapies Launch Pad becomes part of LifeArc
We will be integrating the Rare Therapies Launch Pad (RTLP) into our organisation, marking an important next step in efforts…
-
News releasesWorld-first gene therapy to target devastating rare immune disorder
A first-of-its-kind gene therapy to treat people with CTLA-4 insufficiency, a rare and life-limiting inherited immune disorder, is being advanced…
-
Investigating a novel gene therapy for CTLA-4 insufficiency
Investigating a novel gene therapy for CTLA-4 insufficiency We’re funding a pioneering programme and clinical trial, led by Dr Thomas Fox…
-
Elpida Therapeutics: Accelerating gene therapies for ultra‑rare neurodegenerative diseases
Elpida Therapeutics: Accelerating gene therapies for ultra‑rare neurodegenerative diseases We’ve partnered with Elpida Therapeutics to advance the clinical development of…